Search Technologies
Displaying 1 - 10 of 41 results
Researchers at the University of Maryland have created hundreds of innovations that are available for licensing. Our Discovery Portfolio contains an exciting mix of vaccines, drug targets, therapeutics, devices and cutting edge techniques that promise to make a quantifiable impact on human health and the environment.
Search by keyword:
-
Water Proton NMR for Monitoring Sedimentation Process of Multiphase Mixtures
Published Tuesday, June 27, 2023Summary The technology developed by the University of Maryland, Baltimore utilizes water proton Nuclear Magnetic Resonance (NMR) to monitor the sedimentation process in multiphase mixtures in real-time. This analytical method...
Investigator(s): Bruce Yu, Marc Taraban
Categories: Research Tools, Antibodies, & Reagents, Therapeutics, Small molecules, Chemicals, Biologics, Vaccines
Keyword(s): Sedimentation Monitoring, Multiphase Mixtures, Water Proton NMR, Pharmaceutical, Specialty Chemical, Specialty Materials
Docket: BY-2020-149
-
Real Time in-situ Monitoring of Drug Product Degradation Using Water Proton NMR
Published Wednesday, May 17, 2023Summary This technology uses NMR spectroscopy to measure changes in the NMR signal of water, which is sensitive to changes in the chemical environment of the drug molecules it interacts with. This patented method allows for...
Investigator(s): Bruce Yu, Marc Taraban, Katharine Briggs
Categories: Devices, Diagnostics, Therapeutics, Small molecules, Biologics, Vaccines, Vaccine, Other
Keyword(s): NMR, Quality Control, vaccine, Drug Manufacturing, Freeze-Thaw
Docket: BY-2020-079
-
Noninvasive Quantitation of Full Versus Empty Capsids Using Water Proton NMR
Published Wednesday, May 17, 2023Summary This invention proposes a method for using NMR relaxation rates to determine whether capsid preparations contain empty or full viral capsids and to quantify the capsid content of the preparation....
Investigator(s): Bruce Yu, Marc Taraban
Categories: Devices, Diagnostics, Therapeutics, Small molecules, Biologics, Vaccines, Vaccine, Other
Keyword(s): NMR, Quality Control, vaccine, Drug Manufacturing, Freeze Thaw
Docket: BY-2020-059
-
Detection of Pharmaceutical Product Freezing History using Water Proton NMR
Published Wednesday, May 17, 2023Summary Researchers at UMB have created an innovative method that employs water proton nuclear magnetic resonance (NMR) spectroscopy to detect the freezing history of pharmaceutical products. This technology compares the...
Investigator(s): Bruce Yu, Marc Traban, Katharine Briggs
Categories: Devices, Therapeutics, Biologics, Vaccines, Vaccine, Other
Keyword(s): NMR, Quality Control, vaccine, Drug Manufacturing, Freeze-Thaw
Docket: BY-2019-081
-
Optimized Shigella-ETEC Vaccine with Broad-Spectrum Protection
Published Friday, April 22, 2022UMB’s optimized Shigella-ETEC vaccine is designed to provide enhanced & essential protection against the clinically important species & serotypes of Shigella and Enterotoxigenic Escherichia coli (ETEC), the major causes of dehydrating diarrheal illness among children under 5 years old in low to middle-income countries...
Investigator(s): Eileen M. Barry & Myron M. Levine
Categories: Vaccines
Keyword(s): Vaccine; diarrheal disease prevention; travelers
Docket: EB-2018-077
-
Live Attenuated Non-Transmissible (“LANT”) Vaccines
Published Wednesday, August 18, 2021Non-typhoidal Salmonella (“NTS”) infections are the leading cause of foodborne deaths worldwide, with ~ 80 million (86%) of human NTS infections estimated as foodborne [Majowicz et al, 2010 Clin Infect Dis]. Moreover, multiple outbreaks are reported due to contact with infected animals (e.g., poultry, pigs, cattle, and pets). The...
Investigator(s): Sharon Tennant and James Galen
Categories: Vaccines
Keyword(s): vaccine, salmonella, NTS, AMR
Docket: ST-2019-013
-
Novel strategies for engineering foreign protein-encoding cassettes into bacterial chromosomal DNA
Published Thursday, November 21, 2019Loss of protein expression is a major problem in protein therapy and live vector vaccination, wherein loss of therapeutic dosage often results in treatment failure. Plasmid DNA, when used as a pharmaceutical agent, allows for real-time protein expression, but is easily lost during bacterial multiplication. In order to achieve sufficiently...
Investigator(s): James E Galen, Jin Yuan Wang
Categories: Vaccines
Keyword(s): vaccine
Docket: JG-2013-037
-
Stable Immunogen Based on Inner Domain of HIV-1 GP120 for Inducing Immunity Against HIV
Published Monday, February 5, 2018Antiviral therapy and prevention strategies have made a tremendous impact on the spread of Human Immunodeficiency Virus (HIV-1). However, an HIV vaccine is highly sought after to treat and prevent HIV. This technology is a set of stable protein immunogens comprised of portions of the inner domain of the HIV-1 gp120 protein for potential...
Investigator(s): Marzena Pazgier, William Tolbert, Neelakshi Gohain, George Lewis
Categories: Vaccines
Keyword(s): vaccine, HIV
Docket: MP-2014-131
-
Gonorrhea Vaccine
Published Wednesday, August 19, 2015BackgroundNeisseria gonorrhoeae (GC), the causative agent of the sexually transmitted infection gonorrhea, is the second most common notifiable infection in the United States. Untreated GC infections can result in reproductive complications in women. Fortunately, there are antibacterial treatments available for gonorrhea. However,...
Categories: Vaccines
Keyword(s): Infectious disease, sexually transmitted disease
Docket: LS-2015-100
-
Immunotherapeutic Potential of Modified Lipooligosaccharides/Lipid A: A Platform for “Custom-designed Adjuvants”
Published Wednesday, November 12, 2014Lipid A, the hydrophobic anchor of lipopolysaccharide (LPS), can stimulate the innate immune system via Toll-like receptor 4/myeloid differentiation factor 2 (TLR4/MD2), leading to the release of inflammatory cytokines/chemokines and type I interferons. In turn, this response increases the host’s ability to eradicate a pathogen and supports...
Investigator(s): Robert K Ernst, Adeline Hajjar, Mark Pelletier
Categories: Platforms, Biologics, Vaccines, Biological, Vaccine, Other
Keyword(s): adjuvant, subunit vaccine, lipid A, platform, lipopolysaccharide, immunostimulation custom synthesis
Docket: RE-2012-067